Cargando…

Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats

Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencke, Norbert, Bäumer, Wolfgang, Fraatz, Kristine, Krebber, Ralph, Schneider, Marc, Blazejak, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/
https://www.ncbi.nlm.nih.gov/pubmed/37456557
http://dx.doi.org/10.1016/j.crpvbd.2023.100126
_version_ 1785072906596777984
author Mencke, Norbert
Bäumer, Wolfgang
Fraatz, Kristine
Krebber, Ralph
Schneider, Marc
Blazejak, Katrin
author_facet Mencke, Norbert
Bäumer, Wolfgang
Fraatz, Kristine
Krebber, Ralph
Schneider, Marc
Blazejak, Katrin
author_sort Mencke, Norbert
collection PubMed
description Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a T(max) of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks.
format Online
Article
Text
id pubmed-10344656
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103446562023-07-14 Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats Mencke, Norbert Bäumer, Wolfgang Fraatz, Kristine Krebber, Ralph Schneider, Marc Blazejak, Katrin Curr Res Parasitol Vector Borne Dis Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a T(max) of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks. Elsevier 2023-06-22 /pmc/articles/PMC10344656/ /pubmed/37456557 http://dx.doi.org/10.1016/j.crpvbd.2023.100126 Text en © 2023 Vetoquinol S.A. Lure, France https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova
Mencke, Norbert
Bäumer, Wolfgang
Fraatz, Kristine
Krebber, Ralph
Schneider, Marc
Blazejak, Katrin
Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title_full Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title_fullStr Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title_full_unstemmed Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title_short Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
title_sort plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (felpreva®) and of intravenous administration of the individual active ingredients in cats
topic Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/
https://www.ncbi.nlm.nih.gov/pubmed/37456557
http://dx.doi.org/10.1016/j.crpvbd.2023.100126
work_keys_str_mv AT menckenorbert plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats
AT baumerwolfgang plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats
AT fraatzkristine plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats
AT krebberralph plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats
AT schneidermarc plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats
AT blazejakkatrin plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats